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of the literature. Eur Spine J. 2009;18:1257-65.TABLE 1. Clinical characteristics and hemodynamic data of the patients
Patient
no. Sex Diagnosis
Fontan Death
Age (y) Type Age (y) Cause
1 F SV 9 APC 20 HF
2 M SV 16 LT 18 FF
3 F PAIVS 8 APC 13 FF
4 M SV 8 APC 15 FF
5 F DORV 3 LT 13 HF
6 M SV 3 LT 4 Inf
7 M SV 3 LT 3 FF
8 F DORV 2 ECC 3 HF
9 F TA 7 APC 16 SD
10 M SV 4 ECC 7 SD
MPAP, Mean pulmonary arterial pressure; TPG, transpulmonary gradient; PVR, pulmonar
single ventricle; APC, atriopulmonary connection; HF, heart failure; LT, lateral tunnel; F
double-outlet right ventricle; Inf, infection; NA, not available; ECC, extracardiac conduit;
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tebroplasty. Anesth Analg. 2007;104:924-6.Attenuation of bone morphogenetic protein receptor type 2
expression in the pulmonary arteries of patients with failed Fontan
circulationHidekazu Ishida, MD, Shigetoyo Kogaki, MD, Kunihiko Takahashi, MD, PhD, and
Keiichi Ozono, MD, PhD, Osaka, JapanThe Fontan procedure is a standard treatment for complex
congenital heart defects when biventricular repair cannot
be performed. Although the outcomes of the Fontan proce-
dure have been improved recently, some patients still have
failure of the Fontan circulation, with consequences such as
exercise intolerance, protein-losing enteropathy, and plastic
bronchitis, which is at least partially attributable to highpulmonary vascular resistance. We previously reported
that endothelin-1 and its receptors were overexpressed in
the pulmonary arteries of patients with failed Fontan circu-
lation1; however, the pathobiology of pulmonary arterial re-
modeling in these patients remains unclear.
Because heterozygous mutations in bone morphogenetic
protein receptor type 2 (BMPR2) have been identified in pa-
tients with familial and idiopathic pulmonary arterial hyper-
tension, bone morphogenetic protein (BMP) and its signal
transduction were thought to be critical in pulmonary
arterial hypertension pathogenesis.2 Bone morphogenetic
protein signaling plays a pivotal role in regulating cell pro-
liferation, differentiation, and apoptosis. Impairment of
BMPR2 function thus may cause pulmonary vascular re-
modeling and increase pulmonary vascular resistance. Pre-
vious studies have shown that reduced BMPR2 expression
is also associated with secondary pulmonary arterial hyper-
tension. Our study is the first to demonstrate attenuation ofMPAP (mm Hg) TPG (mm Hg) PVR (U/m2)
Pre Post Pre Post Pre Post
12 11 6 3 1.0 2.3
13 26 5 14 1.6 3.8
12 16 6 7 0.9 3.6
9 13 5 9 1.2 3.8
15 22 4 5 3.0 3.1
10 15 6 5 2.0 NA
14 18 6 16 1.4 NA
18 13 5 4 2.2 1.9
11 NA 5 NA 1.0 NA
10 9 7 5 0.8 2.6
y vascular resistance; Pre, before Fontan operation; Post, after Fontan operation; SV,
F, Fontan failure; PAIVS, pulmonary atresia with intact ventricular septum; DORV,
TA, tricuspid atresia; SD, sudden cardiac death.
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FIGURE 1. Immunohistochemical and quantitative real-time polymerase chain reaction analyses of bone morphogenetic protein receptor type 2 (BMPR2)
expressions in pulmonary arteries of patients who died after the Fontan procedure. A, Elastica–van Gieson stains of the pulmonary arteries of patients with
failed Fontan circulations show severe intimal (arrowheads) and medial (arrows) hypertrophy (a, b, and c) relative to healthy control samples (d). B, In
healthy control subjects, bone morphogenetic protein receptor type 2 is strongly expressed on endothelium in both proximal and distal pulmonary arteries
(arrowheads). C, In contrast, in patients with failed Fontan circulations, bone morphogenetic protein receptor type 2 expression is significantly decreased. D,
The result of computational mean optical density analyses of pulmonary bone morphogenetic protein receptor type 2 expression. bone morphogenetic pro-
tein receptor type 2 expression levels are significantly lower in the failed Fontan circulation (FF) and heart failure (HF) groups than in the control (NC)
group. Asterisk indicates P<.01. E, SDþ INF, Sudden cardiac death plus infectious cause of death. The quantitative real-time polymerase chain reaction
analyses of bone morphogenetic protein receptor type 2 messenger RNA (mRNA) expressions in the lung tissues. Asterisk indicates P<.01.
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Case ReportsBMPR2 expression in the pulmonary arteries of patients
with failed Fontan circulations.
MATERIALS AND METHODS
Ten autopsy lung tissue samples were obtained from patients who had
died after the Fontan procedure between 1992 and 2000. We divided the
patients into 3 subgroups according to their clinical courses and hemody-
namic data: failed Fontan circulation (preserved ventricular function
with high transpulmonary gradient, n¼ 4), heart failure (severe ventricular
dysfunction with relatively low transpulmonary gradient, n ¼ 3), and sud-
den cardiac death or death from infection (n ¼ 3). Age-matched subjects
without any cardiovascular disease (n ¼ 4) were included as a control
group. Table 1 shows the clinical features and hemodynamic data of the pa-
tients. The hemodynamic parameters were extracted from the catheteriza-
tion data just before the Fontan procedure and the latest catheterization data
after the Fontan procedure. Histologic, immunohistochemical, and quanti-
tative real-time polymerase chain reaction analyses were performed to de-
termine the pulmonary BMPR2 expressions in the lung tissues. Results are
expressed as mean  SE. Statistical analyses were performed with Tukey-
Kramer multiple comparison tests.
RESULTS
The small muscular arteries of the patients with failed
Fontan circulations showed not only medial hypertrophy
but also severe intimal thickening (Figure 1, A). The per-
centage wall thicknesses of the proximal (>200 mm) and
intra-acinar arteries (50–200 mm) were significantly higher
in the failed Fontan circulation group than in the control and
sudden cardiac death plus infection groups (for>200-mm
arteries, failed Fontan, 27.1%  3.4%; heart failure,
21.9%  2.6%; sudden cardiac death plus infection,
17.4%  2.4%; control, 14.4%  2.0%; for 50- to 200-
mm arteries, failed Fontan, 39.6%  6.4%; heart failure,
25.8%  1.5%; sudden cardiac death plus infection,
16.7%  4.1%; control, 14.2%  2.5%).
The endothelial cells of normal pulmonary arteries
showed strong positive immunostaining for BMPR2,
whereas the vascular smooth muscle cells showed only
weak staining (Figure 1,B). The endothelial BMPR2 expres-
sionwas significantly lower in the patientswith failed Fontan
circulations than in the control patients (Figure 1, C). The
mean optical density of BMPR2 immunostaining of arteries
with different sizes, quantified by computational analyses,
showed that the BMPR2 expression levels were significantly
lower in the failed Fontan circulation and heart failure groups
than in the control group (Figure 1, D).
BMPR2 messenger RNA expression was significantly
lower in the failed Fontan circulation and heart failure
groups than in the control group (Figure 1, E). This resulte26 The Journal of Thoracic and Cardiovascular Surgwas consistent with the findings of the immunohistochemi-
cal staining, suggesting a significant reduction in the ex-
pression of BMPR2 messenger RNA in the pulmonary
arteries of the patients with failed Fontan circulations.
DISCUSSION
This is the first study that has shown a significant reduc-
tion in BMPR2 expression in patients with failed Fontan cir-
culations. Bone morphogenetic protein signaling regulates
endothelial cell survival and vascular smooth muscle cell
apoptosis.2 A reduced pulmonary BMPR2 level thus may
induce pulmonary endothelial dysfunction and extensive
proliferation of pulmonary vascular smooth muscle cells,
resulting in vascular remodeling (Figure 1, A) and an eleva-
tion in pulmonary vascular resistance. Although the mech-
anisms of downregulation of BMPR2 expression in patients
with failed Fontan circulation are unclear, hypoxia and cy-
tokines have been suggested to cause BMPR2 downregula-
tion.3,4 An abnormal ventilation–perfusion distribution has
also been reported after the Fontan operation.5 We therefore
speculate that hypoxia in the local pulmonary areas, some
cytokines induced by local inflammation or thrombosis, or
both may be involved in the attenuation of BMPR2 expres-
sion. When the Fontan circulation begins to deteriorate in
patients, these factors (hypoxia, cytokines, and inflamma-
tion) can downregulate BMPR2 expression. BMPR2 down-
regulation may be a key pathologic factor in failure of
Fontan circulation. We think that the bone morphogenetic
protein pathway is a potential therapeutic target in the treat-
ment for failing Fontan circulation, as it is for pulmonary ar-
terial hypertension.References
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